Thrombocytopenia and New Thrombosis After Cardiac Surgery
A 67-year-old man is postoperative day 8 after a three-vessel coronary artery bypass graft. He received unfractionated heparin intraoperatively and has been on subcutaneous heparin 5,000 units every 8 hours for venous thromboembolism prophylaxis. His preoperative platelet count was 265 × 10^9/L. Today’s platelet count is 84 × 10^9/L, confirmed on a citrated sample. He has new swelling of the right calf, and duplex ultrasound shows a popliteal vein thrombosis. He is febrile to 38.1°C, and his medications include aspirin, metoprolol, atorvastatin, and furosemide. There is no evidence of disseminated intravascular coagulation; fibrinogen is 410 mg/dL, and the peripheral smear shows no schistocytes. The surgical team asks whether the thrombocytopenia is dilutional from bypass and whether they can continue heparin prophylaxis. The laboratory has a PF4/heparin ELISA and can send a serotonin release assay to a reference laboratory.
1. Calculate the 4T score and interpret the probability of heparin-induced thrombocytopenia.
Read the worked answer
The 4T score is 7, which is high probability. Thrombocytopenia: the platelet count fell from 265 to 84 × 10^9/L, a greater than 50% fall with a nadir above 20 × 10^9/L, so 2 points. Timing: the fall occurs on postoperative day 8, within the typical 5- to 10-day window after heparin exposure, so 2 points. Thrombosis: there is a new confirmed popliteal vein thrombosis, so 2 points. Other causes: cardiopulmonary bypass, postoperative state, and medications make other causes possible but not definite, so 1 point. The total is 7. A high 4T score does not confirm heparin-induced thrombocytopenia, but it is sufficient to stop heparin and start a non-heparin anticoagulant while awaiting PF4 antibody testing. The absence of schistocytes and the normal fibrinogen argue against disseminated intravascular coagulation as the explanation.
2. What immediate actions should be taken, including laboratory testing and anticoagulation?
Read the worked answer
Stop all heparin immediately, including subcutaneous prophylaxis and heparin flushes. Send a PF4/heparin ELISA; if the ELISA is positive or the clinical probability remains high, send a serotonin release assay for confirmation, but do not wait for the result before treating. Start a non-heparin anticoagulant such as argatroban or bivalirudin. Argatroban is hepatically cleared and requires dose adjustment in hepatic impairment; bivalirudin is renally cleared. Avoid platelet transfusion because it may worsen the prothrombotic state. Do not start warfarin alone. If warfarin is needed later, overlap it with a non-heparin anticoagulant until the platelet count has recovered and warfarin has reached therapeutic effect. Monitor the platelet count and watch for new thrombosis. Document the heparin exposure and ensure that all heparin-containing products, including catheter flushes, are discontinued.
3. Why are platelet transfusion and warfarin monotherapy potentially harmful in this setting?
Read the worked answer
In heparin-induced thrombocytopenia, the problem is a prothrombotic state driven by platelet-activating antibodies, not simple platelet deficiency. Transfusing platelets can provide additional platelet substrate for thrombin generation and has been associated with arterial and venous thrombosis, so it is avoided unless there is life-threatening bleeding or another compelling indication. Warfarin monotherapy is dangerous because it can precipitate venous limb gangrene and skin necrosis. Warfarin reduces protein C and protein S before it lowers the vitamin K-dependent clotting factors, creating a transient hypercoagulable state while the heparin-induced thrombocytopenia is still active. If warfarin is used, it must be overlapped with a non-heparin anticoagulant after platelet recovery. The immediate priority is to stop heparin and anticoagulate with a non-heparin agent.